GlassScriptPhysician profile
Kelsey Bodell
NPI 1215585237
$6,141.25
in general payments reported to CMS, 2019-2025
45 companies · $934 in 2025
The $934 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,309 · 2022: $628 · 2023: $923 · 2024: $1,347 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.38 |
| Education | $375.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.68 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $454.24 | 2021 | |
| Genzyme Corporation | $425.44 | 2023-2025 | |
| Ucb, INC. | $416.24 | 2021-2025 | Bimzelx |
| Biogen, INC. | $400.92 | 2021-2022 | |
| Lilly USA, LLC | $346.15 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $285.71 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $278.71 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $259.89 | 2021-2024 | Otezla |
| Dermavant Sciences, INC. | $172.67 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $171.99 | 2023-2025 | |
| Janssen Biotech, INC. | $157.89 | 2023-2024 | Tremfya |
| Allergan, INC. | $133.83 | 2021 | |
| Kyowa Kirin, INC. | $132.38 | 2021-2022 | |
| Lundbeck LLC | $119.79 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Bodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.